FKBP5 and central nervous system cancer: Similarly, Li et al. (2020) showed that the full-length FKBP51 (isoform 1) inhibits glioma cell proliferation, reduces glioma cell viability, and enhances sensitivity to the chemotherapeutic agent carmustine (BCNU).